
Opinion|Videos|September 6, 2024
Addressing Unmet Needs and Emerging Agents
Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Despite the available treatment options, what are the remaining unmet needs or areas requiring further research and development in the management of disease states driven by type 2 inflammation?
- What emerging agents in the pipeline are you most excited for?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances
5










































